CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Somatic mutations in RAF kinases can drive cancer development.
• The role of CRAF mutations in non-small cell lung cancer (NSCLC) is not well understood.

Purpose of the Study:

• To investigate novel somatic CRAF mutations in NSCLC patients.
• To characterize the functional impact of identified CRAF mutations on cellular signaling and oncogenic potential.

Main Methods:

• Screening of NSCLC patient tumors for somatic mutations.
• Functional analysis of CRAF mutations in cell lines (HEK293T, BEAS-2B) and mouse embryonic fibroblasts.
• Assessment of ERK pathway activation and cell proliferation.
• Evaluation of drug sensitivity to RAF and MEK inhibitors.

Main Results:

• Two novel somatic CRAF mutations, CRAF^P261A and CRAF^P207S, were identified in NSCLC patients.
• CRAF^P261A expression increased ERK pathway activation, reduced negative regulatory phosphorylation, and induced anchorage-independent growth.
• CRAF^P207S did not show a gain-of-function effect.
• Type II RAF inhibitors, alone or in combination with MEK inhibitors, suppressed CRAF^P261A-driven signaling and growth.

Conclusions:

• The CRAF^P261A mutation confers oncogenic properties to cells.
• NSCLC cells with CRAF^P261A mutations are sensitive to combined MEK and type II RAF inhibitors.
• CRAF mutations warrant further diagnostic and therapeutic investigation in lung and other cancers.